BAX
Baxter International
$19.66
▼ 1.2%Updated Today 7:15 PM ET
▼ Down 33.3% over the last 12 months
Market Cap
$10.27B
P/E
—
Forward P/E (est.)
—
ROE
-16.4%
Revenue Growth
-4.8%
EPS Growth
—
Profit Margin
-9.7%
FCF Yield
12.7%
Debt / Equity
1.55x
ROIC
-2.0%
Interest Coverage
—
Current Ratio
1.85x
Dividend Yield
0.2%
Implied Growth (rev. DCF)
5.6%
Rating Score
18/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BAX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BAX trades near $19.66, around its 50-day average ($18.42) and 200-day average ($19.70). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. BAX's is $0.72 (~3.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BAX found buyers near $18.01 (support) and sellers near $21.30 (resistance); its 52-week range is $15.73–$31.76. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Baxter International (BAX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $10.27B.
In its latest reported year it generated about $11.24B in revenue and posted a net loss of $957.00M.
Our model rates BAX Weak (18/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-1.9%
Revenue moved from $12.15B in 2021 to $11.24B in 2025, a -1.9% compound annual growth rate. The most recent year declined 4.8% year over year. Shrinking revenue is worth a closer look — is it cyclical or structural?
Gross Margin
30.1%
Operating Margin
-2.7%
Net Margin
-8.5%
ROE
-16.4%
Baxter International keeps about -9.7% of each sales dollar as net profit, with a 30.1% gross margin and -2.7% operating margin. Return on equity is -16.4% and return on invested capital about -2.0%. The company is currently unprofitable on a net basis.
Total Debt
$9.44B
Net Debt
$7.42B
Net Debt / EBITDA
—
Debt / Equity
1.55x
Leverage: debt-to-equity is 1.5x, with a current ratio of 1.9x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $9.44B of total debt against $2.02B of cash.
Operating CF
$845.00M
Free Cash Flow
$332.00M
FCF Margin
3.0%
In the latest year Baxter International produced about $845.00M of operating cash flow and $332.00M of free cash flow after capital spending. That is a free-cash-flow yield of about 12.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
—
P/S
0.94x
P/B
1.56x
EV / EBITDA
26.73x
BAX trades at n/a trailing earnings, 0.9x sales, and 1.6x book value. Reverse-engineering today's price implies the market expects roughly 5.6% long-term free-cash-flow growth. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How BAX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), BAX ranks #58 of 59 by our overall rating.
P/E vs sector
—
median 25.4x
ROE vs sector
-16.4%
median 14.9%
Growth vs sector
-4.8%
median 7.9%
Sector rank
#58
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$9.09 – $15.14
vs. $19.66 today · expected CAGR -14% – -5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $11.58B | $11.93B | $12.29B | $12.66B | $13.03B |
| Net income | $347.44M | $357.86M | $368.60M | $379.66M | $391.05M |
| EPS | $0.67 | $0.69 | $0.71 | $0.74 | $0.76 |
| Share price (low) | $8.07 | $8.31 | $8.56 | $8.82 | $9.09 |
| Share price (high) | $13.45 | $13.86 | $14.27 | $14.70 | $15.14 |
| CAGR (low–high) | -59% / -32% | -35% / -16% | -24% / -10% | -18% / -7% | -14% / -5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BAX:
- Healthy free-cash-flow yield (~12.7%) funds buybacks and dividends.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against BAX:
- Revenue growth is slow/negative (-4.8%), limiting the upside engine.
- Thin net margins (-9.7%) leave little room for error.
- Elevated leverage (debt/equity 1.5x) adds financial risk.
- Our model's overall read is Weak (18/100).
Balance-sheet risk — debt/equity of 1.5x magnifies the impact of higher rates or weaker earnings.
Growth risk — sluggish revenue (-4.8%) leaves little margin for execution missteps.
Margin risk — thin profitability (-9.7%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Baxter International is a large-cap health care business with shrinking revenue, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Weak (18/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.